Literature DB >> 25546768

Effective dosing strategies for therapeutic immunoglobulin: managing wear-off effects in antibody replacement to immunomodulation.

S A Misbah1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25546768      PMCID： PMC4285497          DOI： 10.1111/cei.12517

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  13 in total

1.  Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy.

Authors:  Yusuf A Rajabally; Hanny Seow; Patrick Wilson
Journal:  J Peripher Nerv Syst       Date:  2006-12       Impact factor: 3.494

2.  Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection.

Authors:  Vincent R Bonagura; Robert Marchlewski; Amanda Cox; David W Rosenthal
Journal:  J Allergy Clin Immunol       Date:  2008-07       Impact factor: 10.793

3.  Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.

Authors:  Mary Lucas; Martin Lee; Jenny Lortan; Eduardo Lopez-Granados; Siraj Misbah; Helen Chapel
Journal:  J Allergy Clin Immunol       Date:  2010-05-14       Impact factor: 10.793

4.  Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD.

Authors:  Melvin Berger
Journal:  J Clin Immunol       Date:  2011-06-04       Impact factor: 8.317

5.  Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.

Authors:  Jordan S Orange; William J Grossman; Roberta J Navickis; Mahlon M Wilkes
Journal:  Clin Immunol       Date:  2010-08-01       Impact factor: 3.969

6.  Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report.

Authors:  Patrizia Dacci; Nilo Riva; Marina Scarlato; Irmgard Andresen; Dirksteffen Schmidt; Giancarlo Comi; Raffaella Fazio
Journal:  Neurol Sci       Date:  2010-06-24       Impact factor: 3.307

7.  Pulmonary abnormalities in patients with primary hypogammaglobulinemia.

Authors:  L Kainulainen; M Varpula; K Liippo; E Svedström; J Nikoskelainen; O Ruuskanen
Journal:  J Allergy Clin Immunol       Date:  1999-11       Impact factor: 10.793

8.  A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study.

Authors:  Siraj A Misbah; Andreas Baumann; Raffaella Fazio; Patrizia Dacci; Dirk S Schmidt; Janet Burton; Matthias Sturzenegger
Journal:  J Peripher Nerv Syst       Date:  2011-06       Impact factor: 3.494

Review 9.  CIDP - the relevance of recent advances in Schwann cell/axonal neurobiology.

Authors:  John D Pollard; Patricia J Armati
Journal:  J Peripher Nerv Syst       Date:  2011-03       Impact factor: 3.494

10.  Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.

Authors:  Richard A C Hughes; Peter Donofrio; Vera Bril; Marinos C Dalakas; Chunqin Deng; Kim Hanna; Hans-Peter Hartung; Norman Latov; Ingemar S J Merkies; Pieter A van Doorn
Journal:  Lancet Neurol       Date:  2008-02       Impact factor: 44.182
View more
  5 in total

Review 1.  Considerations for dosing immunoglobulin in obese patients.

Authors:  J P Hodkinson
Journal:  Clin Exp Immunol       Date:  2017-04-17       Impact factor: 4.330

2.  Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of Treatment.

Authors:  Nicholas L Rider; Carleigh Kutac; Joud Hajjar; Chris Scalchunes; Filiz O Seeborg; Marcia Boyle; Jordan S Orange
Journal:  J Clin Immunol       Date:  2017-05-23       Impact factor: 8.317

3.  Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles.

Authors:  Jordan K Abbott; Sanny K Chan; Morgan MacBeth; James L Crooks; Cathy Hancock; Vijaya Knight; Erwin W Gelfand
Journal:  PLoS One       Date:  2022-03-22       Impact factor: 3.240

Review 4.  Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders.

Authors:  Eric M Tichy; Barbara Prosser; Drew Doyle
Journal:  J Pharm Pract       Date:  2020-07-17

5.  Prevalence and Impact of Fatigue in Children with Primary Immunodeficiency Disorders: a Quantitative Single-Center Study.

Authors:  Eline Visser; Pieter Fraaij; Annemieke Hoogenboom; Erica Witkamp; Linda van der Knaap; Annemarie van Rossum; Kim Stol; Clementien Vermont
Journal:  J Clin Immunol       Date:  2022-05-10       Impact factor: 8.542
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.